公开(公告)号：US20120283275A1

公开(公告)日：2012-11-08

申请号：US13467761

申请日：2012-05-09

申请人： Gayatri Sathyan ,  Suneel Gupta ,  Noymi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff

发明人： Gayatri Sathyan ,  Suneel Gupta ,  Noymi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff

IPC分类号： A61K31/519 ,  A61P25/18

CPC分类号： A61K9/0004 ,  A61K31/519

摘要： Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient.

摘要翻译： 公开了包含苯并异恶唑衍生物的剂型和方法。 更具体地，公开了苯甲异恶唑衍生物的剂型，方法和新用途，其显着降低或基本上消除了当给予患者时苯并异恶唑衍生物的某些副作用。

公开(公告)号：US20110195981A1

公开(公告)日：2011-08-11

申请号：US13012490

申请日：2011-01-24

申请人： Gayatri Sathyan ,  Suneel Gupta ,  Noymi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff

发明人： Gayatri Sathyan ,  Suneel Gupta ,  Noymi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff

IPC分类号： A61K31/519 ,  A61P25/18

CPC分类号： A61K9/0004 ,  A61K31/519

摘要： Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient.

摘要翻译： 公开了包含苯并异恶唑衍生物的剂型和方法。 更具体地，公开了苯甲异恶唑衍生物的剂型，方法和新用途，其显着降低或基本上消除了当给予患者时苯并异恶唑衍生物的某些副作用。

公开(公告)号：US09393192B2

公开(公告)日：2016-07-19

申请号：US12428422

申请日：2009-04-22

申请人： Nyomi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff ,  Suneel K. Gupta ,  Gayatri Sathyan

发明人： Nyomi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff ,  Suneel K. Gupta ,  Gayatri Sathyan

IPC分类号： A61K9/22 ,  A61K9/00 ,  A61K31/506 ,  A61K31/519

CPC分类号： A61K9/0004 ,  A61K9/0053 ,  A61K9/2086 ,  A61K9/209 ,  A61K31/506 ,  A61K31/519

摘要： Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

摘要翻译： 提供了用于提供帕培酮或利培酮的基本上升释放速率的剂型和方法。 当每天施用一次时，持续释放剂型提供治疗有效的平均稳态血浆普利培酮或利培酮浓度。 这种每天一次的给药方案导致每24小时内出现一次峰值血浆普利培酮或利培酮浓度。 此外，剂量给药后的较晚时间，峰值血浆普利培酮或利培酮浓度发生在比立即释放剂型给药帕立哌酮或利培酮后出现的峰值血浆普利培酮或利培酮浓度更小的程度。

公开(公告)号：US20090202631A1

公开(公告)日：2009-08-13

申请号：US12428422

申请日：2009-04-22

申请人： Nyomi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff ,  Suneel K. Gupta ,  Gayatri Sathyan

发明人： Nyomi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff ,  Suneel K. Gupta ,  Gayatri Sathyan

IPC分类号： A61K31/519 ,  A61K9/20

CPC分类号： A61K9/0004 ,  A61K9/0053 ,  A61K9/2086 ,  A61K9/209 ,  A61K31/506 ,  A61K31/519

摘要： Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

摘要翻译： 提供了用于提供帕培酮或利培酮的基本上升释放速率的剂型和方法。 当每天施用一次时，持续释放剂型提供治疗有效的平均稳态血浆普利培酮或利培酮浓度。 这种每天一次的给药方案导致每24小时内出现一次峰值血浆普利培酮或利培酮浓度。 此外，剂量给药后的较晚时间，峰值血浆普利培酮或利培酮浓度发生在比立即释放剂型给药帕立哌酮或利培酮后出现的峰值血浆普利培酮或利培酮浓度更小的程度。

公开(公告)号：US20050232995A1

公开(公告)日：2005-10-20

申请号：US11051165

申请日：2005-02-04

申请人： Nyomi Yam ,  Iran Reyes ,  Nipun Davar ,  Atul Ayer ,  Julie Lee ,  Sonya Seroff ,  Suneel Gupta ,  Gayatri Sathyan

发明人： Nyomi Yam ,  Iran Reyes ,  Nipun Davar ,  Atul Ayer ,  Julie Lee ,  Sonya Seroff ,  Suneel Gupta ,  Gayatri Sathyan

IPC分类号： A61K31/506 ,  A61K31/519 ,  A61K9/24

CPC分类号： A61K9/0004 ,  A61K9/0053 ,  A61K9/2086 ,  A61K9/209 ,  A61K31/506 ,  A61K31/519

摘要： Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

摘要翻译： 提供了用于提供帕培酮或利培酮的基本上升释放速率的剂型和方法。 当每天施用一次时，持续释放剂型提供治疗有效的平均稳态血浆普利培酮或利培酮浓度。 这种每天一次的给药方案导致每24小时内出现一次峰值血浆普利培酮或利培酮浓度。 此外，剂量给药后的较晚时间，峰值血浆普利培酮或利培酮浓度发生在比立即释放剂型给药帕立哌酮或利培酮后出现的峰值血浆普利培酮或利培酮浓度更小的程度。

公开(公告)号：US20050208132A1

公开(公告)日：2005-09-22

申请号：US11051060

申请日：2005-02-04

申请人： Gayatri Sathyan ,  Suneel Gupta ,  Noymi Yam ,  Iran Reyes ,  Nipun Davar ,  Atul Ayer ,  Julie Lee ,  Sonya Seroff

发明人： Gayatri Sathyan ,  Suneel Gupta ,  Noymi Yam ,  Iran Reyes ,  Nipun Davar ,  Atul Ayer ,  Julie Lee ,  Sonya Seroff

IPC分类号： A61K31/506 ,  A61K31/519 ,  A61K31/42 ,  A61K9/22

CPC分类号： A61K9/0004 ,  A61K31/519

摘要： Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient.

摘要翻译： 公开了包含苯并异恶唑衍生物的剂型和方法。 更具体地，公开了苯甲异恶唑衍生物的剂型，方法和新用途，其显着降低或基本上消除了当给予患者时苯并异恶唑衍生物的某些副作用。

公开(公告)号：US20070166381A1

公开(公告)日：2007-07-19

申请号：US11619468

申请日：2007-01-03

申请人： Iran Reyes ,  Julie Lee ,  Brian Barclay ,  Iswadi Liejanto ,  Nipun Davar

发明人： Iran Reyes ,  Julie Lee ,  Brian Barclay ,  Iswadi Liejanto ,  Nipun Davar

IPC分类号： A61K9/24

CPC分类号： A61K9/0004 ,  A61K31/506

摘要： Disclosed are osmotic dosage forms and methods that provide for fast release of drugs together with controlled release of drugs. In an aspect, disclosed are osmotic dosage forms including: a semi-permeable membrane; a lubricating subcoat located within the semi-permeable membrane; an orifice in the semi-permeable membrane located at an end of the semi-permeable membrane; a drug layer located adjacent to the orifice and within the lubricating subcoat; a push layer located within the lubricating subcoat and on a side of the drug layer opposite from the orifice; wherein an area of the orifice is greater than or equal to about 1,600 mil2; and wherein the drug layer comprises from about 20 wt % to about 90 wt % microcrystalline cellulose, and less than or equal to about 10 wt % of a drug, based on the total weight of the drug layer. Also disclosed are methods of making osmotic dosage forms.

摘要翻译： 公开了提供药物快速释放以及药物控制释放的渗透剂型和方法。 一方面，所公开的是渗透剂型，包括：半透膜; 位于半透膜内的润滑底涂层; 位于半透膜端部的半透膜中的孔口; 邻近孔口并位于润滑底涂层内的药物层; 位于所述润滑底层内并且在所述药物层的与所述孔相对的一侧的推层; 其中所述孔口的面积大于或等于约1,600密耳2; 并且其中基于药物层的总重量，药物层包含约20重量％至约90重量％的微晶纤维素和小于或等于约10重量％的药物。 还公开了制备渗透剂型的方法。

公开(公告)号：US20070190137A1

公开(公告)日：2007-08-16

申请号：US11528053

申请日：2006-09-26

申请人： Reyes Iran ,  Julie Lee ,  Brian Barclay ,  Nipun Davar ,  Ramkumar Subramanian

发明人： Reyes Iran ,  Julie Lee ,  Brian Barclay ,  Nipun Davar ,  Ramkumar Subramanian

IPC分类号： A61K9/24

CPC分类号： A61K9/0004

摘要： Disclosed are osmotic dosage forms including a semi-permeable membrane; a first and a second orifice in the semi-permeable membrane located at opposite ends of the semi-permeable membrane; a controlled release drug layer located adjacent to the first orifice and within the semi-permeable membrane; a fast release drug layer located adjacent to the second orifice and within the semi-permeable membrane; a push layer located within the semi-permeable membrane and between the controlled release drug layer and the fast release drug layer; a barrier layer slidably located between the push layer and the fast release drug layer; and wherein an area of the second orifice is greater than or equal to about 7800 mil2. Also disclosed are methods of making and using such osmotic dosage forms.

摘要翻译： 公开了包括半透膜的渗透剂型; 位于半透膜的相对端的半透膜中的第一和第二孔; 位于所述第一孔附近且位于所述半透膜内的控释药物层; 位于所述第二孔附近且位于所述半透膜内的快速释放药物层; 位于半透膜之间以及控释药物层与快速释放药物层之间的推层; 阻挡层，其可滑动地位于推动层和快速释放药物层之间; 并且其中所述第二孔口的面积大于或等于约7800密耳2。 还公开了制备和使用这种渗透剂型的方法。

公开(公告)号：US07584087B2

公开(公告)日：2009-09-01

申请号：US11099958

申请日：2005-04-06

申请人： Zhang Bao Xu ,  Stephane Olland ,  Scott Wolfrom ,  Karl Malakian ,  Laura Lin ,  Mark Stahl ,  Julie Lee ,  Lori Fitz ,  Rita Greco ,  Divya Chaudhary ,  William Stuart Somers ,  Lidia Mosyak

发明人： Zhang Bao Xu ,  Stephane Olland ,  Scott Wolfrom ,  Karl Malakian ,  Laura Lin ,  Mark Stahl ,  Julie Lee ,  Lori Fitz ,  Rita Greco ,  Divya Chaudhary ,  William Stuart Somers ,  Lidia Mosyak

IPC分类号： G06G7/58 ,  G01N31/00 ,  G01N33/573 ,  G01N33/53 ,  C12Q1/00 ,  C12Q1/48 ,  C12N9/99 ,  C12N9/12

CPC分类号： C12N9/1205 ,  C07K2299/00 ,  C12Q1/485 ,  G01N33/564 ,  G01N33/57426 ,  G01N2500/04

摘要： A three-dimensional structure of human protein kinase C theta (PKCθ) can be used in methods of designing an agent that interacts with PKCθ. The agent can be an inhibitor of PKCθ activity.

摘要翻译： 人蛋白激酶Cθ（PKCθ）的三维结构可用于设计与PKCθ相互作用的试剂的方法中。 该药物可以是PKCθ活性的抑制剂。

公开(公告)号：US20220377251A1

公开(公告)日：2022-11-24

申请号：US17326427

申请日：2021-05-21

申请人： Jeremy Grata ,  Edward Buschelman ,  Julie Lee

发明人： Jeremy Grata ,  Edward Buschelman ,  Julie Lee

IPC分类号： H04N5/247 ,  H04N5/225 ,  H04N7/18 ,  B61L23/00

摘要： A plurality of cameras is secured to railroad ties to take high resolution images of the underside of a train car as it passes over this plurality of cameras. These images are important to insure the structural integrity of the parts of the rail car as well as the connection means—a coupler and pin—between two rail cars. The shutter speed of the cameras is determined by the speed of the train as it passes over the cameras. As the images are taken, the images can be downloaded and sent to a remote location for further analysis.